Please find enclosed Annual report 2024-25 of Godavari Drugs Limited
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts more than Nifty Microcap 250 and 0.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Godavari Drugs Limited has submitted its 37th Annual Report for FY 2024-25 along with the notice for its 37th Annual General Meeting, scheduled for September 27, 2025 via video conferencing. The company reported revenue from operations of ₹11,335.01 lakhs, a significant drop from ₹15,671.19 lakhs in the previous year (about 28% decline). Despite the revenue fall, EBIDTA margin expanded notably to 11.30% from 8.88%, and PAT margin improved to 3.86% from 3.54%. Profit After Tax stood at ₹438.00 lakhs (down from ₹554.89 lakhs), with EPS of ₹5.82. Key AGM items include reappointment of Managing Director Mr. Mukund Kakani, appointment of Mrs. Shilpa Bung as Independent Director, and a proposal to double authorized share capital from ₹10 crore to ₹20 crore, hinting at future fundraising or expansion plans.
For shareholders, the sharp revenue decline is a concern, but improving margins suggest better cost discipline and a richer product mix. The proposed doubling of authorized share capital signals potential capital-raising activity that could dilute existing holdings. A new API manufacturing facility expected to commission by year-end may support future growth.